Status and phase
Conditions
Treatments
About
Study done in young breast cancer patients to prevent chemotherapy induced ovarian failure
Full description
Study Design:
Prospective, randomized, open phase II trial
Schedule:
All patients will receive an anthracycline-containing polychemotherapy.
Patients randomized to Goserelin will receive their first injection of 3.6 mg at least 2 weeks before start of chemotherapy. Goserelin will be given as a subcutaneous injection in the abdominal wall every 4 weeks (28 ± 3 days) until the end of the last chemotherapy cycle.
Primary objective:
•To increase the percentage of patients with normal ovarian function at 6 months after application of (neo)adjuvant, anthracycline-containing polychemotherapy in parallel with Goserelin compared to chemotherapy alone.
Secondary objectives:
To compare the two treatment groups regarding
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal